San Diego-based Abreos Biosciences Inc. is looking to create a multiplex test that goes beyond the simple yes/no COVID-19 antibody results and measures the “specific flavors” of antibodies to provide a more complete picture of the antibodies in a person’s blood. Read More →
Abreos Biosciences has been awarded funding for phase two of the "Personalized precision dosing of anti-TNF biological therapies" project by, among others, the National Institute of Health's (NIH). This "Fast Track Award" is the second part of a project focused on treating chronic inflammatory diseases. Read More →
SAN DIEGO (PRWEB) MARCH 26, 2019 Abreos Biosciences, a San Diego-based biotech company and leader in precision dosing of biological therapeutics, is pleased to announce a research collaboration with the FDA’s Center for Drug Evaluation and Research (CDER) to develop several... Read More →
Abreos Biosciences announced the U.S. launch of moNATor, a laboratory-developed test that can help physicians monitor the levels of Tysabri (natalizumab) in patients with multiple sclerosis (MS). Tysabri (approved for relapsing forms of MS, by Biogen) administered at a dose of 300 mg every four weeks... Read More →
Abreos Biosciences, a San Diego-based biotech company and a leader in the precision dosing of biological therapeutics, is pleased to announce that it has completed a new investment round. The funding came from existing investors as well as new investor TLP Investment Partners LLC and its affiliates.